<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056836</url>
  </required_header>
  <id_info>
    <org_study_id>FVF2598g</org_study_id>
    <nct_id>NCT00056836</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether injections of rhuFab V2 into the eye can&#xD;
      prevent vision loss in patients with age-related macular degeneration, and also to evaluate&#xD;
      the safety of this treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>720</enrollment>
  <condition>Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhuFab V2 (ranibizumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age &gt;=50 years&#xD;
&#xD;
          -  Active primary or recurrent subfoveal choroidal neovascularization (CNV) lesions&#xD;
             secondary to age-related macular degeneration (AMD) in the study eye&#xD;
&#xD;
          -  Lesions with occult CNV or with some classic CNV component are permissible. However,&#xD;
             if classic CNV (well-demarcated hyperfluorescence boundaries in the early phase of the&#xD;
             fluorescein angiogram) is present, the area of classic CNV must be &lt;50% of the total&#xD;
             lesion size.&#xD;
&#xD;
          -  The total area of CNV (including both classic and occult components) encompassed&#xD;
             within the lesion must be &gt;=50% of the total lesion area.&#xD;
&#xD;
          -  The total lesion area must be &lt;=12 disc areas (DA) in size.&#xD;
&#xD;
          -  Best corrected visual acuity, using Early Treatment of Diabetic Retinopathy Study&#xD;
             (ETDRS) charts, of 20/40 to 20/320 (Snellen equivalent) in the study eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with verteporfin, external-beam radiation therapy, or transpupillary&#xD;
             thermotherapy (TTT) in the study eye&#xD;
&#xD;
          -  Treatment with verteporfin in the non-study eye less than 7 days preceding Day 0&#xD;
&#xD;
          -  Previous participation in a clinical trial (for either eye) involving anti-angiogenic&#xD;
             drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)&#xD;
&#xD;
          -  Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or&#xD;
             device implantation) in the study eye&#xD;
&#xD;
          -  Previous subfoveal focal laser photocoagulation in the study eye&#xD;
&#xD;
          -  Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month&#xD;
             preceding Day 0&#xD;
&#xD;
          -  History of vitrectomy surgery in the study eye&#xD;
&#xD;
          -  History of submacular surgery or other surgical intervention for AMD in the study eye&#xD;
&#xD;
          -  Previous participation in any studies of investigational drugs within 1 month&#xD;
             preceding Day 0 (excluding vitamins and minerals)&#xD;
&#xD;
          -  Subretinal hemorrhage in the study eye that involves the center of the fovea, if the&#xD;
             size of the hemorrhage is either &gt;=50% of the total lesion area or &gt;=1 disc area in&#xD;
             size&#xD;
&#xD;
          -  Subfoveal fibrosis or atrophy in the study eye&#xD;
&#xD;
          -  CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or&#xD;
             pathologic myopia&#xD;
&#xD;
          -  Retinal pigment epithelial tear involving the macula in the study eye&#xD;
&#xD;
          -  Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic&#xD;
             retinopathy) that, in the opinion of the investigator, could either: (1) Require&#xD;
             medical or surgical intervention during the 24-month study period to prevent or treat&#xD;
             visual loss that might result from that condition, or (2) If allowed to progress&#xD;
             untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of&#xD;
             best corrected visual acuity over the 24-month study period&#xD;
&#xD;
          -  Active intraocular inflammation (grade trace or above) in the study eye&#xD;
&#xD;
          -  Current vitreous hemorrhage in the study eye&#xD;
&#xD;
          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the&#xD;
             study eye&#xD;
&#xD;
          -  History of idiopathic or autoimmune-associated uveitis in either eye&#xD;
&#xD;
          -  Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye&#xD;
&#xD;
          -  Aphakia or absence of the posterior capsule in the study eye&#xD;
&#xD;
          -  Spherical equivalent of the refractive error in the study eye demonstrating more than&#xD;
             -8 diopters of myopia&#xD;
&#xD;
          -  Intraocular surgery (including cataract surgery) in the study eye within 2 months&#xD;
             preceding Day 0&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure &gt;= 30 mmHg&#xD;
             despite treatment with anti-glaucoma medication)&#xD;
&#xD;
          -  History of glaucoma filtering surgery in the study eye&#xD;
&#xD;
          -  History of corneal transplant in the study eye&#xD;
&#xD;
          -  Premenopausal women not using adequate contraception&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that might affect interpretation&#xD;
             of the results of the study or render the subject at high risk for treatment&#xD;
             complications&#xD;
&#xD;
          -  Current treatment for active systemic infection&#xD;
&#xD;
          -  History of allergy to fluorescein, not amenable to treatment&#xD;
&#xD;
          -  Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality&#xD;
             to be analyzed and graded by the central reading center&#xD;
&#xD;
          -  Inability to comply with study or follow up procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.</citation>
    <PMID>17021318</PMID>
  </results_reference>
  <results_reference>
    <citation>Su√±er IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3629-35. doi: 10.1167/iovs.08-3225. Epub 2009 Feb 28.</citation>
    <PMID>19255158</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>March 24, 2003</study_first_submitted>
  <study_first_submitted_qc>March 25, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2003</study_first_posted>
  <last_update_submitted>May 14, 2014</last_update_submitted>
  <last_update_submitted_qc>May 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Neovascular age-related macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

